Paula Roberta Aguiar Pastrez

Dr. Paula Roberta Aguiar Pastrez


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
ESEstela Maria Silva
Estela Maria Silva
VMVânia Sammartino Mariano
Vânia Sammartino Mariano
PPPaula Roberta Aguiar Pastrez
Paula Roberta Aguiar Pastrez
MPMiguel Cordoba Pinto
Miguel Cordoba Pinto
ENEmily Montosa Nunes
Emily Montosa Nunes
ALAdhemar Longatto-Filho
Adhemar Longatto-Filho
The pathogenesis of lung cancer is triggered by a combination of genetic and environmental factors, being the tobacco smoke the most important risk factor. Nevertheless, the incidence of lung cancer in non-smokers is gradually increasing, which demands the search for different other etiological factors such as occupational exposure, previous lung disease, diet among others. In the early 80’s a theory linked specific types of human papillomavirus (HPV) to lung cancer due to morphological similarities of a subset of bronchial squamous cell carcinomas with other HPV-induced cancers. Since then, several studies revealed variable rates of HPV DNA detection. The current study aimed to provide accurate information on the prevalence of HPV DNA in lung cancer. Biopsies were collected from 77 newly diagnosed non-small cell lung cancer (NSCLC) patients treated at the Thoracic Oncology Department at Barretos Cancer Hospital. The samples were formalin fixed and paraffin embedded (FFPE), histologic analysis was performed by an experienced pathologist. DNA was extracted from FFPE material using a commercial extraction kit and HPV DNA detection was evaluated by multiplex PCR and HPV16 specific real-time PCR. HPV was not identified in any of the samples analysed (69). Our data demonstrated a lack of HPV DNA in a series of NSCL cancers.

13 October 2017 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
ACAllini Mafra da Costa
Allini Mafra da Costa
JFJosé Humberto T.G. Tavares Guerreiro Fregnani
José Humberto T.G. Tavares Guerreiro Fregnani
PPPaula Roberta Aguiar Pastrez
Paula Roberta Aguiar Pastrez
VMVânia Sammartino Mariano
Vânia Sammartino Mariano
ESEstela Maria Silva
Estela Maria Silva
ALAdhemar Longatto-Filho
Adhemar Longatto-Filho
Esophageal squamous cell carcinoma (ESCC) is a highly lethal malignant tumor. Currently, Human papillomavirus (HPV) is suggested as a potential risk factor for esophageal cancer (EC) in addition to the classic risk factors, alcohol and tobacco, but this hypothesis still remains contradictory. We sought to investigate wether HPV and well-known biomarkers (p16 and p53) and patient-related factors that may have impact on survival of ESCC. We conducted a prospective cohort study. By using multiplex PCR, we determined the prevalence of high risk HPV in ESCC, and evaluated the immunohistochemical expression of p16 and p53, molecular markers related to esophageal carcinogenesis in order to verify the potential influence of these variables in patients’s survival. Survival rates were estimated using Kaplan-Meier methods. A multivariate confirmatory model was performed using Cox proportional hazards regression. Twelve (13.8%) of 87 patients were HPV-DNA positive. Positive reactions of p16 and p53 were 10.7% and 68.6%, respectively. Kaplan-Meier analysis indicated that men (p = 0.025) had poor specific-cancer survival and a shorter progression-free survival (p = 0.050) as compared to women; III or IV clinical stage (p < 0.019) had poor specific-cancer survival and a shorter progression-free survival (p < 0.001) compared to I and II clinical stage; not submitted to surgery (<0.001) and not submitted to chemoradiotherapy (p = 0.039) had a poor specific-cancer survival, as well. The multivariate analysis showed that HPV, p16 and p53 status are not predictive parameters of progression-free and specific-cancer survival. HPV infection and p53 and p16 expression are not prognostic factors in ESCC.

27 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PPPaula Roberta Aguiar Pastrez
Paula Roberta Aguiar Pastrez
ABAna Barbosa
Ana Barbosa
VMVânia Sammartino Mariano
Vânia Sammartino Mariano
RCRhafaela Lima Causin
Rhafaela Lima Causin
ACAntónio Gil Castro
António Gil Castro
ALAdhemar Longatto-Filho
Adhemar Longatto-Filho
Esophageal squamous cell carcinoma (ESCC) is a common type of cancer characterized by fast progression and high mortality rates, which generally implies a poor prognosis at time of diagnosis. Intricate interaction networks of cytokines produced by resident and inflammatory cells in the tumor microenvironment play crucial roles in ESCC development and metastasis, thus influencing therapy efficiency. As such, cytokines are the most prominent targets for specific therapies and prognostic parameters to predict tumor progression and aggressiveness. In this work, we examined the association between ESCC progression and the systemic levels of inflammatory cytokines to determine their usefulness as diagnostic biomarkers. We analyzed the levels of IL-1β, IL-6, IL-8, IL-10, TNF-α e IL-12p70 in a group of 70 ESCC patients and 70 healthy individuals using Cytometric Bead Array (CBA) technology. We detected increased levels of IL-1β, IL-6, IL-8, and IL-10 in ESCC patients compared to controls. However, multivariate analysis revealed that only IL8 was an independent prognostic factor for ESCC, as were the well-known risk factors: alcohol consumption, tobacco usage, and exposure to pesticides/insecticides. Importantly, patients with low IL-6, IL-8, TNM I/II, or those who underwent surgery had a significantly higher overall survival rate. We also studied cultured Kyse-30 and Kyse-410 cells in mice. We determined that the ESCC cell line Kyse-30 grew more aggressively than the Kyse-410 cell line. This enhanced growth was associated with the recruitment/accumulation of intratumoral polymorphonuclear leukocytes. In conclusion, our data suggest IL-8 as a valuable prognostic factor with potential as a biomarker for ESCC.